(±)-trans-6-methylpiperidin-3-ol hydrochloride | 67459-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (±)-trans-6-methylpiperidin-3-ol hydrochloride
• 英文别名: 6-Methylpiperidin-3-ol hydrochloride；6-methylpiperidin-3-ol;hydrochloride
• CAS: 67459-74-9
• 化学式: C₆H₁₃NO*ClH
• 分子量: 151.636
• InChiKey: PVOAKSPCPLYSNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.54
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (±)-trans-6-methylpiperidin-3-ol hydrochloride 在 锂硼氢 、 silica gel 、 三乙胺 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 (2R,5S)-5-羟基-2-甲基哌啶-1-羧酸苄酯
  参考文献：
  名称：

  双（二氟甲基）三甲基硅酸根阴离子：Me3SiCF2H可烯化酮的亲核二氟甲基化的关键中间体

  摘要：

  通过亲核碱金属盐和18-冠冕-6活化Me 3 SiCF 2 H首次观察到五配位双（二氟甲基）硅酸根阴离子[Me 3 Si（CF 2 H）2 ] -。通过调谐导致与我可烯醇化的酮的高效，催化亲核二氟甲基的发现和开发的抗衡作用在其反应性的进一步研究3 SICF 2通过使用CSF和18-冠-6作为引发体系的组合小时。机理研究表明，[（18-crown-6）Cs] + [Me 3 Si（CF 2 H）2 ]-是该催化反应的关键中间体。

  DOI：

  10.1002/anie.201605280
• 作为产物：
  描述：

  3-羟基-6-甲基吡啶 在 盐酸 、 platinum(IV) oxide 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 70.0 ℃ 、5.07 MPa 条件下， 反应 8.0h， 生成 (±)-trans-6-methylpiperidin-3-ol hydrochloride
  参考文献：
  名称：

  双（二氟甲基）三甲基硅酸根阴离子：Me3SiCF2H可烯化酮的亲核二氟甲基化的关键中间体

  摘要：

  通过亲核碱金属盐和18-冠冕-6活化Me 3 SiCF 2 H首次观察到五配位双（二氟甲基）硅酸根阴离子[Me 3 Si（CF 2 H）2 ] -。通过调谐导致与我可烯醇化的酮的高效，催化亲核二氟甲基的发现和开发的抗衡作用在其反应性的进一步研究3 SICF 2通过使用CSF和18-冠-6作为引发体系的组合小时。机理研究表明，[（18-crown-6）Cs] + [Me 3 Si（CF 2 H）2 ]-是该催化反应的关键中间体。

  DOI：

  10.1002/anie.201605280

文献信息

• [EN] HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE SUBSTITUÉS PAR UN GROUPE HYDROXY
  申请人：MERCK SHARP & DOHME

  公开号：WO2014176142A1

  公开（公告）日：2014-10-30

  The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂的羟基化合物。本发明还涉及所述化合物在潜在治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进素受体的疾病中的用途。
• [EN] 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE TYPE 2-PYRYDYLOXY-4-ESTER ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099696A1

  公开（公告）日：2014-06-26

  The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-酯类化合物，其为俄雷欣受体拮抗剂。本发明还涉及在俄雷欣受体参与的神经和精神障碍和疾病的潜在治疗或预防中使用本文所述的2-吡啶氧基-4-酯类化合物。本发明还涉及包含这些化合物的药物组合物。本发明还涉及在俄雷欣受体参与的这些疾病的预防或治疗中使用这些药物组合物。
• [EN] 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES 2-PYRIDYLOXY-4-ÉTHER DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137883A1

  公开（公告）日：2014-09-12

  The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved..

  本发明涉及2-吡啶氧基-4-醚化合物，这些化合物是促进睡眠的受体拮抗剂。本发明还涉及在潜在治疗或预防神经系统和精神疾病中使用本文所述的2-吡啶氧基-4-醚化合物。本发明还涉及包括这些化合物的药物组合物。本发明还涉及在预防或治疗涉及促进睡眠的受体的这些疾病中使用这些药物组合物。
• [EN] 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS 2-PYRIDYLOXY-3-ESTER-4-ÉTHER ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015088864A1

  公开（公告）日：2015-06-18

  The present invention is directed to 2-pyridyloxy-3-ester-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促醒素受体的拮抗剂2-吡啶氧基-3-酯基-4-醚化合物。本发明还涉及在潜在的治疗或预防神经和精神疾病中使用本文所述的2-吡啶氧基-4-醚化合物。本发明还涉及包含这些化合物的药物组合物。本发明还涉及在预防或治疗促醒素受体参与的这类疾病中使用这些药物组合物。
• [EN] PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS PIPÉRIDINYLOXY LACTONE SERVANT D'ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095442A1

  公开（公告）日：2015-06-25

  The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对奥雷克星受体的拮抗剂-哌啶氧代内酯化合物。本发明还涉及所述哌啶氧代内酯化合物在潜在的涉及奥雷克星受体的神经和精神障碍和疾病的治疗或预防中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及奥雷克星受体的疾病中的用途。